Corporate$TGTX8:52 AM ETdeveloping · v2

TG Therapeutics Reports Seven-Year BRIUMVI Data, Subcutaneous and Single-Dose Progress

By BORSA NewsroomPublished Oct 21, 2026, 8:52 AM EDTUpdated Oct 21, 2026, 8:52 AM EDT

TG Therapeutics presented seven-year BRIUMVI data showing 88% of patients free from disability progression, Phase 1 subcutaneous bioavailability data supporting quarterly dosing, and Phase 3 ENHANCE results supporting single-dose initiation. azer-cel CAR-T data to be presented Oct 23.

Sentimentbullish 80

Strongly bullish · 80 of 100

Impact60

medium · sector-wide

Confidence90%

high confidence · 2 wires

Eventdeveloping

v2 · alerted to followers

WHAT WE KNOW

Seven-year continuous BRIUMVI: 88.3% free from 24-week confirmed disability progression, ARR 0.018